Business Context and Reporting Period
This Form 8-K is a current report filed by Trovagene, Inc. (not Cardiff Oncology, Inc.) on July 20, 2016, with the report date finalized on July 26, 2016. The company is a Delaware corporation focused on developing diagnostic tests, specifically the Trovera™ urine- and blood-based liquid biopsy tests for assessing EGFR T790M mutational status.
Key Financial Metrics and Debt Structure
The filing details a material amendment to the company's existing debt facility rather than reporting standard quarterly financial metrics like revenue or cash flow.
- Debt Instrument: Fifth Amendment to the Loan and Security Agreement with Oxford Finance LLC and Silicon Valley Bank.
- Payment Terms: Interest-only payments required monthly through March 1, 2017.
- Maturity Date: Extended to February 1, 2020.
- Equity Component: Lenders received warrants to purchase an aggregate of 15,496 shares of common stock at an exercise price of $4.84 per share, exercisable for ten years.
The filing text does not provide a clear value for the outstanding principal loan amount, current revenue, profit, or cash flow.
Material Changes and Conditions
The amendment introduces specific performance conditions that must be met to maintain the interest-only payment structure through September 1, 2017:
- Securing agreements with insurance providers/networks resulting in 168 million aggregate U.S. covered lives.
- Placement of Trovera™ EGFR, KRAS, and BRAF products on a list of diagnostic tests at a major U.S. cancer center satisfactory to the Lenders.
Outlook, Risks, and Other Events
Scientific Validation: On July 26, 2016, the company announced study results demonstrating the clinical and analytical validity of its Trovera™ tests for EGFR T790M mutational status.
Financial Reporting: The company scheduled the release of financial results for the second quarter ended June 30, 2016, for August 4, 2016.
Risks: The company's ability to service its debt under the current terms is contingent upon meeting the specific commercial milestones regarding insurance coverage and hospital adoption listed above. Failure to meet these could alter payment obligations.
Investor Verification Checklist
- Verify the exact outstanding principal balance of the loan with Oxford Finance LLC and Silicon Valley Bank.
- Confirm the progress toward the 168 million covered lives insurance milestone.
- Review the upcoming Q2 2016 financial results (scheduled for August 4, 2016) for cash burn rate and liquidity position.
- Assess the status of Trovera™ product placement at major U.S. cancer centers.